Publications

Search our bibliography using the filters on the right-hand side.

Displaying 151 through 200 of 237 publications.

Kawai AT, Anderson S, Andrade SE, Zichittella L, Stockdale C. Developing capabilities to monitor the safety of vaccine use during pregnancy in Sentinel's Prism Program. Presented at the 4th International Neonatal & Maternal Immunization Symposium; September 2017. Brussels, Belgium.

Colosia AD, Yang J, Hillson E, Mauskopf J, Copley-Merriman C, Shinde V, Stoddard J. The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: a systematic review. PLoS One. 2017 Aug 10;12(8):e0182321. doi: 10.1371/journal.pone.0182321

Buck PO, Meyers JL, Gordon LD, Parikh R, Kurosky SK, Davis KL. Economic burden of diagnosed pertussis among individuals with asthma or chronic obstructive pulmonary disease in the USA: an analysis of administrative claims. Epidemiol Infect. 2017 Jul;145(10):2109-21. doi: 10.1017/S0950268817000887.

Wasserman M, Rejas J, Mendez C, Wilson M, McDade C, Moffatt M, Farkouh R. Estimating clinical and economic impact of switching from the 13-valent (PCV13) to the 10-valent (PCV10) Pneumococcal Conjugate Vaccine in Spain. Presented at the 35th Annual Meeting of the European Society for Paediatric Infectious Diseases; May 24, 2017. Madrid, Spain.

Wasserman M, Wilson M, Breton MC, Peloquin F, McDade C, Farkouh R. Estimating the clinical and economic impact of switching from the 13-valent Pneumococcal Conjugate Vaccine (PCV13) to a lower-valent (PCV10) vaccine in Canada. Poster presented at the 35th Annual Meeting of the European Society for Paediatric Infectious Diseases; May 23, 2017. Madrid, Spain.

Talbird SE, La EM, Mauskopf J, Krueger WS, Altland A, Daniels VJ, Pillsbury M, Wolfson LJ. Modeling the impact of exogenous boosting on herpes zoster: an updated methodological review of the varicella zoster virus literature. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 24, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A325.

Talbird SE, La EM, Poston SA, Hogea CS. A budget-impact analysis of quadrivalent influenza vaccine use in the United States. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A73.

Curran D, Van Oorschot D, Buck PO, Patterson BJ, Lee BY, Yawn BP, Hicks KA, Carrico J. Cost-effectiveness analysis of Shingrix for vaccinating US adults against herpes zoster. Presented at the ACIP Herpes Zoster Working Group; May 2017. Atlanta, GA.

Herring W, Rosen B. Early economic model for respiratory syncytial virus vaccination in older adults. Presented at the 2017 Respiratory Syncytial Virus Consortium in Europe; May 2017. Antwerp, Belgium.

La E, Trantham L, Kurosky S, Odom D, Aris E, Hogea C. An analysis of the heterogeneity in adult vaccination coverage in the United States: beyond the national level. Poster presented at the 20th Annual Conference on Vaccine Research; April 24, 2017. Bethesda, MD.

Graham J, Johnson K, Jiang Y, Weiss T. Comparing the estimated potential health impact of 2 herpes zoster vaccines in the United States. Poster presented at the 2017 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 27, 2017. Denver, CO. [abstract] J Manag Care Spec Pharm. 2017 Mar; 23(3a):S3.

Boggess K, Butler A, Layton JB, Li D, Hudgens M, McGrath L, Weber D, Becker-Dreps S. Tdap vaccination rates among 1.2 million privately insured pregnant women, 2010-2014. Poster presented at the 37th Annual Meeting of the Society for Maternal Fetal Medicine: The Pregnancy Meeting; January 2017. Las Vegas, NV. [abstract] Am J Obstet Gynecol. 2017 Jan; 216(Suppl 1):S204. doi: 10.1016/j.ajog.2016.11.594

Wilson M, Wasserman M, Breton MC, McDade C, Earnshaw S, Farkouh R. Potential clinical and economic impact of switching from the 13-valent to 10-valent pneumococcal conjugate vaccine in Canada. Poster presented at the 2016 Canadian Immunization Conference; December 6, 2016. Ottawa, Canada.

Li R, Stewart B, McNeil MM, Duffy J, Nelson J, Kawai AT, Baxter R, Belongia EA, Weintraub E. Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013-2014 and 2014-2015 seasons. Pharmacoepidemiol Drug Saf. 2016 Aug;25(8):928-34. doi: 10.1002/pds.3996

Yih WK, Kulldorff M, Sandhu SK, Zichittella L, Maro JC, Cole DV, Jin R, Kawai AT, Baker MA, Liu C, McMahill-Walraven CN, Selvan MS, Platt R, Nguyen MD, Lee GM. Prospective influenza vaccine safety surveillance using fresh data in the Sentinel System. Pharmacoepidemiol Drug Saf. 2016 May;25(5):481-92. doi: 10.1002/pds.3908

Poulos C. A review of discrete choice experiment studies of preferences for vaccine features. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A220.

Buck PO, Gordon LD, Meyers J, Parikh R, Kurosky S, Davis KL. Economic burden of diagnosed pertussis among individuals with asthma or chronic obstructive pulmonary disease: a US database study. Poster presented at the National Foundation for Infectious Diseases 19th Annual Conference on Vaccine Research; April 2016. Bethesda, MD.

Kawai AT, Martin D, Kulldorff M, Li L, Cole DV, McMahill-Walraven CN, Selvam N, Selvan MS, Lee GM. Febrile seizures after 2010-2011 trivalent inactivated influenza vaccine. Pediatrics. 2015 Oct;136(4):e848-855. doi: 10.1542/peds.2015-0635

Talbird SE, Mauskopf JA, Yang K. Review of cost-effectiveness analyses of varicella vaccination: which model structure assumptions and input parameters matter? Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.

Baker MA, Lieu TA, Li L, Hua W, Qiang Y, Kawai AT, Fireman BH, Martin DB, Nguyen MD. A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program. Am J Epidemiol. 2015 Apr 15;181(8):608-18. doi: 10.1093/aje/kwu322

Jackson ML, Rothman KJ. Effects of imperfect test sensitivity and specificity on observational studies of influenza vaccine effectiveness. Vaccine. 2015 Mar 10;33(11):1313-6. doi: 10.1016/j.vaccine.2015.01.069

Poulos C, Johnson FR, Krishnarajah F, Anonychuk A, Misurski D. Pediatricians' preferences for infant meningococcal vaccination. Value Health. 2015 Jan;18(1):67-77. doi: 10.1016/j.jval.2014.10.010

Talbird SE, Graham JB, Mauskopf JA, Masseria C, Krishnarajah G. Impact of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine use in wound management on health care costs and pertussis cases. J Manag Care Pharm. 2015 Jan;21(1):88-99.

Kawai AT, Martin D, McMahill-Walraven C, Selvam N, Selvan M, Lee G, Mini-Sentinel PRISM Team. Validation of febrile seizures identified in the Mini-Sentinel Post-Licensure Rapid Immunization Safety Monitoring (PRISM) system. Poster presented at the 2014 Infectious Diseases Society of America; October 10, 2014. Philadelphia, PA.

Kawai AT. Assessment of febrile seizures after trivalent influenza vaccines during the 2010-2011 influenza season in PRISM. Presented at the Brookings Institution Roundtable on Active Medical Product Surveillance; July 21, 2014.

Davis KL, Kurosky SK. Recent trends in incidence of infant pertussis hospitalization in the United States. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014.

Davis KL, Kurosky SK. Recent trends in costs, length of stay, and mortality associated with infant pertussis hospitalization in the United States. Presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014.

Kurosky SK, Davis KL, Karve SJ. Tetanus toxoid, reduced diphtheria toxoid, and acellular puertussis (TDAP) vaccine compliance among adolescents in the United States, 2010-2012. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014.

Kawai AT. Febrile seizures after TIV: PRISM System, 2010-2011 influenza season. Presented at the 2014 Advisory Committee on Immunization Practices (ACIP); June 2014. Atlanta, GA.

Kawai AT, Li L, Kulldorff M, Vellozzi C, Weintraub E, Baxter R, Belongia EA, Daley MF, Jacobsen SJ, Naleway A, Nordin JD, Lee GM. Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season. Pharmacoepidemiol Drug Saf. 2014 May;23(5):548-53. doi: 10.1002/pds.3575

Villa M, Black S, Groth N, Rothman KJ, Apolone G, Weiss NS, Aquino I, Boldori L, Caramaschi F, Gattinoni A, Malchiodi G, Crucitti A, Della Cioppa G, Scarpini E, Mavilio D, Mannino S. Safety of mf59-adjuvanted influenza vaccination in the elderly: results of a comparative study of mf59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy. Am J Epidemiol. 2013 Oct;178(7):1139-45.

Kim D, Lauria DT, Poulos C, Dong B, Whittington D. Effect of travel distance on household demand for typhoid vaccines: implications for planning. Int J Health Plann Manage. 2013 Mar 12;Advance Online.

Karve S, Candrilli S, Kappelman MD, Tolleson-Rinehart S, Tennis P, Andrews E. Healthcare utilization and comorbidity burden among children and young adults in the United States with Systemic Lupus Erythematosus or Inflammatory Bowel Disease. J Pediatr. 2012 Oct 1;161(4):662-670.e. doi: 10.1016/j.jpeds.2012.03.045

Tse (Kawai) A, Tseng HF, Greene SK, Vellozzi C, Weintraub E, McCarthy N. Risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Poster presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2012. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2012 Aug; 21(Suppl 3):365-6.

Mauskopf J, Talbird S, Standaert B. Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models. Expert Rev Pharmacoecon Outcomes Res. 2012 Jun 1;12(3):357-71.

Thompson JR, Talbird SE, Mauskopf JA, Brogan AJ, Standaert B. Translating outcomes from a dynamic transmission model for vaccination to cost-effectiveness estimates: the impact of different analytic approaches on the results. Presented at the 2012 ISPOR 17th Annual International Meeting; June 6, 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A10.

Earnshaw SR, McDade CL, Zanotti G, Farkouh RA, Strutton D. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada. BMC Infect Dis. 2012 Apr 1;12:101.

Strutton DR, Farkouh RA, Earnshaw SR, Hwang S, Theidel U, Kontodimas S, Klok R, Papanicolaou S. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands. J Infect. 2012 Jan 1;64(1):54-67.

Earnshaw SR, McDade CL, Zanotti G, Farkouh R, Strutton D. Cost-effectiveness of 2+1 dosing of 13-valent pneumococcal conjugate vaccine compared with 2+1 dosing of 10-valent conjugate vaccine in preventing pneumococcal disease in Canada. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 9, 2011. [abstract] Value Health. 2011 Nov; 14(7):A275.

Talbird S, Knerer G, Hausdorff W, Taylor T, Frostad CR. Reply to Strutton et al.: response to “Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries”. Vaccine. 2011 Oct 1;29(44):7591-2.

Poulos C, Yang JC, Levin C, Minh HV, Giang KB, Nguyen D. Mothers' preferences and willingness to pay for HPV vaccines in Vinh Long Province, Vietnam. Soc Sci Med. 2011 Jul 1;73(2):226-34.

Roussy JP, Kwan H, Earnshaw SR, Farkouh RA, Hwang S, Strutton D. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine compared with 10-valent vaccine in preventing pneumococcal infections in Quebec. Poster presented at the 9th Canadian Immunization Conference; December 2010. Previously presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy.

Talbird SE, Taylor TN, Caporale J, Ismaila AS, Gomez J. Residual economic burden of Streptococcus pneumoniae- and nontypeable Haemophilus influenzae- associated disease following vaccination with PCV-7: a multicountry analysis. Vaccine. 2010 Nov 19;28(Suppl 6):G14-22.

Talbird SE, Taylor TN, Knoll S, Frostad CR, Marti SG. Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. Vaccine. 2010 Nov 19;28(Suppl 6):G23-9.

Talbird SE, Ismaila AS, Taylor TN. A steady-state, population-based model to estimate the direct and indirect effects of pneumococcal vaccines. Vaccine. 2010 Nov 19;28(Suppl 6):G3-G13.

Standaert B, Demarteau N, Talbird S, Mauskopf J. Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models? Vaccine. 2010 Nov 19;28(Suppl 6):G30-8.

Roussy JP, Kwan H, Earnshaw SR, Farkouh RA, Hwang S, Strutton D. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine compared with 10-valent vaccine in preventing pneumococcal infections in Quebec. Poster presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2010.

Knoll S, Jochum D, Talbird S. Comparative cost benefit analysis of two new Pneumococcal Conjugate Vaccines (PHiD-CV and PCV-13). Klin Padiatr. 2010 Jun 1;222(Suppl 1):S51-2.

Rousculp M, Gilligan T, Hollis KA, Griffin J, Price MA, Thompson M. Elementary school-based influenza vaccination programs: findings to inform pandemic vaccination campaigns. Poster presented at the Pediatric Academic Society Annual Meeting; May 2010. Previously presented at the 44th Annual National Immunization Conference.

Rousculp M, Gilligan T, Hollis KA, Griffin J, Price MA, Thompson M. Elementary school-based influenza vaccination programs: findings to inform pandemic vaccination campaigns. Poster presented at the 44th Annual National Immunization Conference; April 2010.